ENDOXAN ASTA 1GM INJECTION contains Cyclophosphamide, which belongs to a group of medicines called Alkylating agents. It is used in the treatment of malignant diseases in adults and children such as malignant lymphomas (Stages III and IV), Hodgkin’s disease, Non-Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous leukemia, monocytic leukemia and acute lymphoblastic leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, Ewing’s sarcoma, breast cancer.
ENDOXAN ASTA 1GM INJECTION is also indicated for the treatment of nephrotic syndrome in children who fail to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. ENDOXAN ASTA 1GM INJECTION is not recommended for use in patients with acute infections, bone-marrow aplasia and urinary tract infections like cystitis, acute urothelial toxicity from cytotoxic chemotherapy or radiation therapy or urinary outflow obstruction.
Before receiving ENDOXAN ASTA 1GM INJECTION, inform your doctor if you have had allergic or anaphylactic reactions to other alkylating agents; bone marrow suppression or failure, including leukopenia, neutropenia, thrombocytopenia and anaemia, neutropenic fever, serious infections include pneumonias, bacterial, fungal, viral, protozoal and parasitic infections, severe immune suppression, concomitant chemotherapy and/or radiation therapy, urinary tract and renal diseases like haemorrhagic cystitis, pyelitis, urethritis and haematuria, urotoxicity such as bladder ulceration, necrosis, fibrosis, contracture, urinary tract obstructions or active urinary tract infections, nephrotoxicity, including renal tubular necrosis, heart diseases such as myocarditis, myopericarditis, pericardial effusion including cardiac tamponade and congestive heart failure, ventricular arrhythmias (including atrial fibrillation, flutter, severe QT prolongation with ventricular tachyarrhythmia), pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease, respiratory failure, pneumonitis and secondary malignancies (urinary tract cancer, myelodysplasia, acute leukaemia’s, lymphomas, thyroid cancer, sarcomas and bladder cancer), veno-occlusive liver disease, poor wound healing, hyponatremia and syndrome of inappropriate secretion of antidiuretic hormone.
ENDOXAN ASTA 1GM INJECTION is not recommended for use by pregnant women. ENDOXAN ASTA 1GM INJECTION is generally not recommended for use in breastfeeding women as it may pass through the breast milk. ENDOXAN ASTA 1GM INJECTION should be used with caution in children and the elderly. The most common side effects of receiving ENDOXAN ASTA 1GM INJECTION are nausea, vomiting, weight loss, alopecia, hematuria and leukopenia. Contact your doctor if any of your symptoms get worse or persist.